FGFR2 inhibitor 3HP-2827

An orally bioavailable small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), with potential antineoplastic activity. Upon oral administration, FGFR2 inhibitor 3HP-2827 targets, binds to and inhibits FGFR2, which results in the inhibition of FGFR2-mediated signal transduction pathways. This may inhibit the proliferation of tumor cells that harbor FGFR2 alterations, including amplifications, mutations and fusions. FGFR2, a receptor tyrosine kinase upregulated and mutated in many tumor cell types, plays a key role in cellular proliferation, migration and survival.